预后
总体预后良好。尽管通常在 24-72 小时对治疗产生反应,但复发或症状加重常见。治疗通常还需要 2-3 年。较少见情况下,对于慢性复发性病程,可能需要更长疗程的治疗。PMR 可能也伴有 GCA,如果伴发,其预后和治疗与 GCA 直接相关。[47]Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.http://www.ncbi.nlm.nih.gov/pubmed/12140303?tool=bestpractice.com[48]Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol. 2004;18:705-722.http://www.ncbi.nlm.nih.gov/pubmed/15454128?tool=bestpractice.com
研究表明,复发风险增加或治疗时间长与女性性别、高 ESR(>40 mm/小时)和外周关节炎有关。[49]Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74:1808-1817.http://ard.bmj.com/content/74/10/1808.longhttp://www.ncbi.nlm.nih.gov/pubmed/26359489?tool=bestpractice.com